The Korean Journal of Neurotrauma (KJNT), the official journal of the Korean Neurotraumatology Society and the Korean Spinal Cord Society, is an international, peer-reviewed journal of medicine, biannually (30th April and 31st October) published biannually (April 30th and October 31st) in English. It is the official journal of the Korean Neurotraumatology Society and the Korean Spinal Cord Society. KJNT follows the Open Access journal policy. KJNT and publishes important papers covering the whole entire field of neurosurgery, including basic or clinical studies in central and peripheral injuries. Also, studies on rare cases and technical notes of on special instruments or equipment that may have applications might be useful to the field of neurotraumatology are also acceptable.

MANUSCRIPT SUBMISSION

Authors should submit manuscripts via the electronic manuscript management system (submit.kjnt.org) for KJNT. Manu- scripts should be submitted by the corresponding author, who should indicate the address, phone and fax numbers, and e-mail address for correspondence on the title page of the manuscript. The revised manuscript should be submitted through the same web system under the same identification numbers.

Queries concerning manuscript submission should be directed to:

Editor-in-Chief
Sun-Chul Hwang, MD, PhD
Korean Journal of Neurotrauma
Department of Neurosurgery,
Soonchunhyang University College of Medicine
170 Jomaru-ro Wonmi-gu, Bucheon 14584, Korea
TEL: +82-32-621-5059
FAX: +82-32-621-5016
E-mail: kjnt.editor@gmail.com, schwangns@gmail.com

RESEARCH AND PUBLICATION ETHICS

Research Ethics

Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as http://cris.nih.go.kr, or other sites accredited by the WHO as listed at http://www.who.int/ictrp/en/.

Informed Consent
Copies of written informed consent and IRB approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. In addition, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the Methods section.

Conflict of Interest
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated. These conflicts of interest must be included as a footnote on the title page or in the acknowledgement/acknowledgement section. The corresponding author should certify the disclosure of any conflict of interest with his/her signature.
INSTRUCTIONS FOR AUTHORS

Statement of human and animal rights
Clinical research studies must state that all work was carried out in compliance with the Ethical Principles for Medical Research Involving Human Subjects outlined in the Helsinki Declaration in 1975 (revised in 2000). Clinical studies that do not meet the Helsinki Declaration guidelines will not be considered for publication. Human subjects must not be identifiable. A patient’s name, initials, hospital number, date of birth, or other protected healthcare information must never be disclosed. Animal research studies must state that all work was carried out in compliance with the National or Institutional Guide for the Care and Use of Laboratory Animals; the ethical treatment of all experimental animals must be ensured.

Authorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these the following 4 conditions. The editorial board may ask for contributions of each author and may publish this information. All authors are required to provide his/her “Open Researcher and Contributor iD (ORCiID),” when submitting a manuscript to KJNT. During the submission process, authors will have the option to either create an ORCiD iD or associate an existing ORCiD iD to their account. To learn more about ORCiID, please visit https://orcid.org/about. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the concerned authors concerned. This letter must be signed by all authors on the paper. It is the responsibility of the authors to determine the order of authorship. KJNT will not and cannot take any part in adjudicating authorship disputes. Copyright assignment must be completed by every author.

Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. The duplication will be checked through CrossCheck (http://app.ithenticate.com/) before completion of submission. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, illustrations, and tables.

Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/journals.html).

PEER REVIEW PROCESS
KJNT reviews all manuscripts received. A manuscript is first reviewed for its format, and then sent to the 2 most relevant investigators available for review of the contents. The editor selects peer referees from the Board’s specialist database. Authors’ names and affiliations are removed during peer review.

Acceptance of the manuscript is decided based on the critiques and recommended decision of the referees. A referee may recommend “acceptance,” “minor revisions,” “major revisions,” or “rejection.” If there is a marked discrepancy in the decisions between two referees or between the opinions of the author and referee(s), the Editor may send the manuscript to another referee for additional comments and a recommended decision. Three repeated decisions of “review again after revision” are regarded as a “rejection.” The reviewed manuscripts are returned back to the corresponding author with comments and recommended revisions. Names and decisions of the referees are masked.

Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate any alterations made in response to the referees’ comments item by item in a response note. Please prepare and submit the revised manuscript and another annotated copy describing the changes you have made. The annotated copy should reflect the changes in highlights (i.e., not by using the Track Changes function in MS Word, but by yellow highlighting). Failure to resubmit the revised manuscript within 8 weeks of the editorial decision is regarded as a withdrawal. The editorial office should be notified if additional time is needed or if an author chooses not to submit a revision. The editorial committee makes decisions concerning editing, revision, acceptance, or rejection; editing may include shortening an article, reducing the number of illustrations or tables, or changing the

https://kjnt.org
INSTRUCTIONS FOR AUTHORS

paper’s format or the order of the manuscript. Authors can track the progress of a manuscript on the journal’s website.

COPYRIGHTS AND CREATIVE COMMONS ATTRIBUTION LICENSE

Copyrights of all published materials are owned by the Korean Neurotraumatology Society and must not be published elsewhere without written permission. They also follow the Creative Commons Attribution Non-Commercial License available from: http://creativecommons.org/licenses/by-nc/4.0/.

PUBLICATION PROCESSING CHARGES

Upon submission of a manuscript, the author should send a copy of deposit confirmation to the following account number with the corresponding author’s name on it. The processing charge for one article is KRW 300,000 regardless of the type of article.

MANUSCRIPT PREPARATION

Publication Type

KJNT publishes editorials, review articles, original work (clinical and laboratory research), case reports, letters to the editor, and special articles.

1. Editorials are invited perspectives on an area of neurotrauma, dealing with very active fields of research, current surgical interests, fresh insights, and debates. Editorials should not exceed 600 words, excluding References, Tables, and Figures.

2. Review articles provide a concise review of a subject of importance to neurotrauma researchers written by invited experts in neurotrauma. The manuscript for review articles should be organized in the following order: Title page, Abstract (unstructured) and Keywords, Introduction, Main text (Introduction, Manuscript body, Conclusion), Conflict of interest, Acknowledgments (if necessary), References, Tables, Figures, and Legends. Review articles should not exceed 60,000 words.

3. Original articles are papers reporting the results of clinical investigations, which are sufficiently well documented to be acceptable to critical readers. The manuscript for original articles should be organized in the following order: Title page, Abstract (structured) and Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Conflict of interest, Acknowledgments (if necessary), References, Tables, Figures, and Legends. Original articles should not exceed 40,000 words.

4. Case reports/ideas and innovations deal with clinical cases of surgical interest or innovation. The manuscript for case reports should be organized in the following order: Title page, Abstract (unstructured) and Keywords, Introduction, Case Report, Discussion, Conclusion, Conflict of interest, Acknowledgments (if necessary), References, Tables, Figures, and Legends. The case report and idea innovation should not exceed 20,000 words and 20 References. The Abstract should be unstructured and its length should not exceed 200 words.

5. Letters to the editor or commentary letters: Authors can submit a sound criticism or opinion on a specific article published in the journal, topics of general interest to neurosurgeons, personal views on a specific scientific issue, departmental announcements or changes, conference schedules, and other information on related clinical fields.

6. Special articles are devoted to providing updated reports by specialists in various fields or on significant issues (e.g., history of the field) for members of the society. The authors and topics of special drafts will be assigned and specially requested by the editorial board. In special drafts, the author’s views will be highly respected.

General Guidelines

The manuscript must be written in English only. Author(s) should prepare the Cover letter, Title page, Main manuscript, Table(s), and Figure(s) as separate files. The document files should be submitted in Microsoft Word format (doc or docx). The author should post all relevant files to the online submission system. When submitting the manuscript, the author should provide signed copies of the Journal’s “Form for disclosure of potential conflict of interest” and “Copyright release and author agreement.”

The text of the manuscript, including Tables and Figure legends, must be in standard 11 point font, double-spaced, on A4-size paper.

• Drug and chemical names should be stated in standard chemical or generic nomenclature.

• Units of measurement should be presented according to the International System (SI) of Units. All units must be preceded by one space except angle (°), percentage (%), and temperature (°C).

• Descriptions of genes or related structures in a manuscript should include names and official symbols provided by the US National Center for Biotechnology Information (NCBI) or the HUGO Gene Nomenclature Committee.

• Statistical expression: mean and standard deviation should be described as mean±SD, and mean and standard error as mean±SE. p-values should be described as p<0.05 or p=0.003.

• Generic and brand names of medicines: for medicine, use
generic names. If a brand name should be used, insert it in parentheses after the generic name.

**Reporting Guidelines for Specific Study Designs**
For specific study designs, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table.

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Type of Study</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRISMA</td>
<td>Preferred reporting items of systematic reviews and meta-analyses</td>
<td><a href="http://prisma-statement.org/">http://prisma-statement.org/</a></td>
</tr>
</tbody>
</table>

**MANUSCRIPT PREPARATION FORMAT**

**Cover letter**
The cover letter should inform the editor that neither the submitted material nor portions of it have been previously published or are under consideration for publication elsewhere. The corresponding author should certify that all listed authors participated meaningfully in the study and that they have seen and approved the final manuscript.

**Title Page**
The title page should contain the article title and full names of all authors with their institutional affiliations in English. The type of manuscript (review article, laboratory study, clinical research, and case report) should be also specified. The title should be less than 50 words with a well-understandable topic. When the work includes multiple authors with different affiliations, the institution where the research was mainly conducted should be spelled out first, followed by footnotes in superscript Arabic numerals beside the authors’ names to describe their affiliations in a consecutive order. The title page should also contain the full address, telephone and fax numbers, and e-mail address of the corresponding author at the bottom of the page, as well as information on any previous presentations of the manuscript at conferences, and funding resources, if any. A running head not exceeding 65 characters in English must be included.

**Abstract and Keywords**
All manuscripts must contain an abstract. The abstract should be concise, less than 250 words and describe the Objective, Methods, Results, and Conclusion in a structured format. Abstracts for case reports and reviews should be unstructured and within 200 words. A list of key words, with a maximum of six items, should be included at the end of the abstract. The selection of key words should be based on the Medical Subject Heading (MeSH) of Index Medicus and the website ([https://www.nlm.nih.gov/mesh/MBrowser.html](https://www.nlm.nih.gov/mesh/MBrowser.html)).

**Introduction**
The introduction should concisely address the purpose of the article and include background reports that are relevant to the purpose of the paper (a detailed review of the literature should be addressed in the Discussion section).

**Materials and Methods**
Materials and Methods should include sufficient details on the design, objects, and methods of the article in order, as well as data analysis strategies and control of bias in the study. Please provide sufficient details in the Methodology section of an experimental study so that it can be further replicated. Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study covers an exclusive population, for example in only one sex, authors should justify why, except in obvious cases, (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.

When reporting experiments with human subjects, the authors should indicate whether they received approval from the IRB for the study. When reporting experiments with animal subjects, the authors should indicate whether the handling of animals was supervised by the research board of the affiliated institution or a similar body. Photographs disclosing patient identities must be accompanied by a signed release form from the patient or family permitting publication.

An explanation of the experimental methods should be concise and sufficient for repetition by other qualified investigators. Procedures that have been previously published should not be described in detail. However, new or significant modifications of previously published procedures need full descriptions. The sources of special chemicals or preparations should be stated, along with their location (name of company, city, state, or country). Method of statistical analyses and criteria of significance
level should be described.

**Results**
The authors should logically describe results of their observations and analyses performed using the methodology described in Materials and Methods and provide actual data. For biometric measurements in which considerable stochastic variation exists, a statistical treatment should be used in principle. The results should solely include findings of the current study and not refer to previous reports. While efforts should be made to avoid overlapping descriptions in the Tables and the main text, important trends and points in the Table should be described in the text. Experimental results should be described using Arabic numbers and the SI unit system.

**Discussion**
Discussions about the findings of the research and interpretations in relation to other studies are made. It is necessary to emphasize new and critical findings of the study, and avoid repeating results of the study presented in previous sections. The meaning and limitation of observed facts should be described, and the conclusion should be related to the objective of the study only when it is supported by results of the research. Authors are encouraged to use subheadings in the discussion section to guide readers through a logical flow of thought.

**Conclusion**
The conclusion section should include a concise statement of major findings of the study in accordance with the study’s purpose.

**Conflicts of interest**
Any potential conflict of interest relevant to the article must be described.

**Acknowledgement**
A brief acknowledgement of persons who made a genuine contribution may be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations. All funding related to the work should be specifically acknowledged.

**References**
a) Only references cited in the text must appear in the reference list, cited in the form of a superscript at the end of sentences where they are used in (example: reference\(^{1,15-18}\)). If other author’s names are used in manuscript, the reference list must be marked immediately following the name (example: Majd et al.\(^{14}\) reported an overall recurrent fracture rate of 10%).

b) All references should be alphabetized by the first author’s last name. In instances where both authors share the same last name, the order will be followed by the second author’s first name.

c) When a work has six or less authors, cite the names of all the authors. When a work has over six authors, cite the names of the first six authors, followed by “et al.” A journal title with one word does not need to be written out in abbreviation. For more on references, please refer to the National Library of Medicine (NLM) Style Guide for Authors, Editors, and Publishers (http://www.nlm.nih.gov/citingmedicine). The styles of references are as follows:

**<Journal>**

**<Book>**

**<Book Chapter>**

**<Website>**

**Tables**
Tables should be typed double-spaced on separate pages within the manuscript, and should be titled and numbered in Arabic numerals in the order of their first citation in the text. Each column should be given a short heading. Only the first letter of the first word in each row and column should use capital letters. If numerical measurements are provided, the unit of measurement should be included in each heading. The statistical significance of observed differences in data should be indicated by appropriate statistical analysis. All abbreviations should be defined in footnotes. For special remarks, superscripts \(^*, †, §, ¶, ‡, ††, ‡‡\) should be used. Explanatory material should be placed in
Accepted manuscripts will be managed by the editorial board and the professional manuscript editor. The edited manuscript, which will be emailed to the corresponding author, must be reviewed and revised by the authors and returned to KJNT within 72 hours. The final edited manuscript will be converted into the publication format and posted on the website (www.kjnt.org) as a provisional draft. The authors can proofread the format.

For accepted manuscripts, no significant changes should be made to alter the interpretation of the results. Only minor changes, such as correcting typographical errors or critical changes to maintain the article's accuracy, are allowed. If there are excessive revisions during the author's proofreading process, those changes will not be accepted, and the paper can be considered for re-submission. Authors should do their best to ensure the accuracy of the proofs. After publication, if there are critical errors, they should be corrected as a Corrigendum or Erratum.

The corresponding author will be charged a publication processing fee. If the publication fee is not paid, final publication may be delayed or cancelled.

Figures
All figure legends should be double-spaced. Do not use separate sheets for each legend. Each legend should have a figure title and informative explanations: brief meanings of the data, descriptions of any abbreviations or reference points in the photographs, and identification of all units, mathematical expressions, abscissas, ordinates, and symbols. Description of informed consent for publication is required for figures that include potentially private images. The figures should be numbered Figure 1, Figure 2, and Figure 3, and so on. Related figures should be combined as one figure, with each subfigure denoted by the letters, A, B, C, and so on, following the Arabic number of the main figure (e.g., Figure 1A; Figure 1B and C; Figure 1A-C).

The author is responsible for submitting files of sufficient quality to permit accurate reproduction. All photographs should be correctly exposed and sharply focused. Symbols, arrows, or letters used in photographs should contrast with the background. A legend for each light microscopic photograph should include the name of the stain and magnification (e.g., H&E, ×400); electron microscopic photography should have an internal scale marker. All figures may be reduced, enlarged, or trimmed for publication by the editor.

Figures should be submitted in Tiff or EPS file format. If the only possible file format is JPEG, it must be of the highest quality with minimum compression. It is recommended to size original figure widths to 4 inches wide. The minimum requirements for digital resolution are:
- 300 DPI/PPI for picture-only photographs.
- 600 DPI/PPI for photographs containing pictures and line elements, e.g., text labels, thin lines, arrows.
- 900 DPI/PPI for black and white images, such as line drawings or graphs.